Clinical Trial Update: Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa [Phase 1]

View source ↗

Summary

Phase 1 PK/PD study assessed pharmacokinetic and pharmacodynamic interactions between three single doses of BIA 9-1067 and a single dose of controlled-release L…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 9-1067
• Levodopa/Carbidopa (levodopa/carbidopa)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson's Disease (PD) | Phase 1 | Status: COMPLETED | Results posted: 2015-01-21